{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"244"}]}],"title":"Total Number of Changes to BVCA"},{"categories":[{"measurements":[{"groupId":"OG000","value":"125"}]}],"title":"Grade 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"111"}]}],"title":"Grade 2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}],"title":"Grade 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Grade 4"}],"denomUnitsSelected":"BVCA Changes","denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"},{"counts":[{"groupId":"OG000","value":"244"}],"units":"BVCA Changes"}],"description":"Ocular toxicity as measured by changes to BVCA as measured per the Keratopathy Visual Acuity scale, and graded using belantamab mafodotin REMS \\[Risk Evaluation and Mitigation Strategies\\] guidelines. BVCA changes from baseline are categorized as normal or grade 1, 2, 3, or 4 and are based on the worst overall finding. Normal: No decline from baseline on Snellen Visual Acuity. Grade 1: Decline from baseline of 1 line on Snellen Visual Acuity. Grade 2: Decline from baseline of 2 or 3 lines on Snellen Visual Acuity, and not worse than 20/200. Grade 3: Decline from baseline of more than 3 lines on Snellen Visual Acuity, and not worse than 20/200. Grade 4: Snellen Visual Acuity worse than 20/200. The Data table reports the total number of BVCA changes experienced, along with counts and percentage by grade of change.","groups":[{"description":"Participants with relapsed and/or refractory multiple myeloma who were treated with Belantamab Mafodotin - blmf (BLENREP) in the DCI Oncology outpatient clinics between August 5, 2020 and November 7, 2023","id":"OG000","title":"Multiple Myeloma/Blenrep Participants"}],"paramType":"COUNT_OF_UNITS","populationDescription":"The 30 patients in the study experienced ocular toxicity (changes to BVCA) a total of 244 times as reported during clinic visits. The analysis population is the 244 BVCA changes reported.","reportingStatus":"POSTED","timeFrame":"Between baseline and earliest of end of BLENREP treatment, death, lost to contact or end of study timeframe, up to 40 months.","title":"Ophthalmology: Grade of Ocular Toxicities [Changes to Best-Corrected Visual Acuity (BCVA)]","type":"POST_HOC","typeUnitsAnalyzed":"BVCA Changes","unitOfMeasure":"BVCA Changes"}